## Hormonal Therapy for Stage IC-III ER/PR Positive Breast Cancer

## **PQRI Data Collection Sheet**

			/ / [	🗆 Male 🛛 Female
Patient's Name Practice Medical Record Number (MRN)			Birth Date (mm/dd/yyyy)	Gender
National Provider Identifier (NPI)			Date of Service	
Clinical Information			Billing Information	
Step 1 Is patient eligible for this measure?				
Step 1 is patient engine for this measure:	Vee	Na	Onde Demuined on Oleim Form	
Patient is aged 18 years and older.	Yes	No	Code Required on Claim Form Verify date of birth on claim form.	
Patient is aged 16 years and older.				
Patient has a diagnosis of breast cancer.			Refer to gender on claim form.         Refer to coding specifications document for list of applicable codes.	
There is a CPT E/M Service Code for this visit.				
If <b>No</b> is checked for any of the above, STOP. Do not report a CPT category II code.				
Step 2 Does patient also have other requirements <sup>1</sup> for this measure?				
	Yes	No	Code to be Reported on Line 24D of (or Service Line 24 of Electronic Cl	•
Does patient have estrogen receptor (ER) or progesterone receptor (PR) positive breast cancer?			If <b>No</b> (ie, estrogen receptor (ER) ar receptor (PR) negative breast canc 3316F and STOP.	
			OR	
			If estrogen receptor (ER) and proge status is not documented, report 3	
			If <b>Yes</b> (ie, estrogen receptor (ER) or receptor (PR) positive breast cance next question.	
For patient with ER/PR positive breast cancer (from above), does patient also have Stage 1C (T1c, tumor size > 1 cm to 2 cm), Stage II, or Stage III breast cancer documented?			If <b>No</b> , report <b>only</b> the appropriate c to stage as listed below and STOP. (Do not report a code for ER/PR S <sup>-</sup>	
			Stage 0 Stage I (tumor size ≤ 1 cm) Stage IV Cancer stage not documented	3303F <sup>2</sup> 3312F
			If <b>Yes</b> , report 3315F for ER/PR por appropriate code that corresponds below and proceed to Step 3.	
			Stage IC (tumor size > 1 cm to 2 cm Stage IIA Stage IIB Stage IIIA Stage IIIB Stage IIIB	3315F and 3306F 3315F and 3307F 3315F and 3309F 3315F and 3310F

continued on next page

## Hormonal Therapy for Stage IC-III ER/PR Positive Breast Cancer

continued from previous page

Clinical Information			Billing Information
Step 3 Does patient meet or have an acceptable reason for not meeting the measure?			
Tamoxifen or Aromatase Inhibitor	Yes	No	Code to be Reported on Line 24D of Claim Form, if Yes (Or Service Line 24 of Electronic Claim Form)
Prescribed <sup>4</sup>			4179F
<ul> <li>Not prescribed or received for the following reason:</li> <li>Medical (eg, patient's disease has progressed to metastatic; patient is receiving a gonadotropin-releasing hormone analogue, patient has received oophorectomy, patient is receiving radiation or chemotherapy, patient's diagnosis date was ≥ 5 years from reporting date)</li> </ul>			4179F–1P
Patient (eg, patient refusal)			4179F–2P
<ul> <li>System (eg, patient is currently enrolled in a clinical trial)</li> </ul>			4179F-3P
Document reason here and in medical chart.			If <b>No</b> is checked for <b>all</b> of the above, report 4179F–8P (ie, Tamoxifen or aromatase inhibitor <i>not</i> prescribed, reason not otherwise specified.)

<sup>1</sup>There are 2 additional requirements for patients to be eligible for this measure: Stage IC through IIIC breast cancer AND estrogen receptor (ER) OR progesterone receptor (PR) positive breast cancer. If patient does not meet these requirements, only one code should be reported for this measure. Report only the code for the requirement that patient does not meet.

<sup>2</sup>Report 3303F for the following Stage I Breast Cancers:

T1mic — Microinvasion 0.1 cm or less in greatest dimension

T1a — Tumor more than 0.1 cm but not more than 0.5 cm in greatest dimension

T1b — Tumor more than 0.5 cm but not more than 1 cm in greatest dimension

<sup>3</sup>Report 3305F for Stage T1c Breast Cancer-Tumor more than 1 cm but not more than 2 cm in greatest dimension.

<sup>4</sup>The reporting clinician is not required to have written the initial prescription.

PQRI 2008 Measure 71, Effective Date 01/01/2008

© 2007 American Medical Association, American Society of Clinical Oncology, and National Comprehensive Cancer Network. All Rights Reserved. (Disclaimers, Copyright and other Notices indicated on the Coding Specifications document are incorporated by reference.) CPT<sup>®</sup> copyright 2007 American Medical Association